Delving into the Latest Updates on Allogeneic adipose tissue-derived mesechymal stromal cells(Cell2Cure ApS) with Synapse

Overview

Basic Info

Drug Type

Mesenchymal stem cell therapy

Synonyms

C2C_ASC110

Target-

Action-

Mechanism-

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart failure with reduced ejection fraction

Inactive Indication-

Originator Organization

Cell2Cure ApS

Active Organization-

Inactive Organization-

License Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to investigate the efficacy and safety of intravenous infusions of allogeneic adipose tissue-derived mesechymal stromal cells in patients with recently diagnosed non-ischemic heart failure in restoring cardiac function compared to placebo. The primary outcome of this trial is the change in left ventricular ejection fraction 6 month after treatment compared to placebo. Participants will be given two treatments with one month apart of either allogeneic adipose tissue-derived mesechymal stromal cells or placebo.

Start Date01 Mar 2026

Sponsor / Collaborator-

CTIS2025-523699-21-00

/ Not yet recruitingPhase 1IIT

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms

Start Date01 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Allogeneic adipose tissue-derived mesechymal stromal cells(Cell2Cure ApS)

Login to view more data

100 Translational Medicine associated with Allogeneic adipose tissue-derived mesechymal stromal cells(Cell2Cure ApS)

Login to view more data

100 Patents (Medical) associated with Allogeneic adipose tissue-derived mesechymal stromal cells(Cell2Cure ApS)